Nanexa: New evaluation agreement in mAb space - ABG

Signs evaluation agreement with "large global pharma company"
To evaluate PharmaShell in depot formulation of monoclonal antibody
Not a new field for Nanexa: already generated promising mAb data


New evaluation agreement with large global pharma company

Nanexa has announced today that it has signed a new Material Transfer and Feasibility Study Agreement agreement with a large global pharmaceutical company (company undisclosed). The agreement is to evaluate PharmaShell in a depot formulation of a monoclonal antibody.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nanexa/Equity-research/2023/11/nanexa---new-evaluation-agreement-in-mab-space/